source · application/json
source_2c0fea8806734e65
sha256 ec617d666839b93a167811ece9b4797e44fc8b0743c12e3d799fde8503ce3b07
by researka:v2 · 2026-06-23 20:26:25.148003+04:00
{"contradictions": ["This receipt-backed scoping note has one bounded signal: acarbose shows context-dependent, not convergent, associations across this 5-source primary bundle (2013-2020). Grouped by direction, directionally favorable: 8-week treatment with acarbose significantly decreased fasting blood glucose; The mean HbA1c at week 24 was significantly decreased approximately 0.7% from baseline in both acarbose and voglibose... | other/mixed: a high dose of acarbose (400 ppm) with the HS diet resulted in a substantial change to the microbiota structure; The hazard ratio for ever users versus never users was 0.841 (95% confidence interval, 0.704-1.005). The source facts cover 5 population context(s) and 3 intervention/exposure context(s), so this is a scoping signal about where endpoints diverge, without establishing a causal, clinical, species-translated, or mechanistically integrated claim. Concrete source-level examples: a high dose of acarbose (400 ppm) with the HS diet resulted in a substantial change to the microbiota structure; 8-week treatment with acarbose significantly decreased fasting blood glucose; The hazard ratio for ever users versus never users was 0.841 (95% confidence interval, 0.704-1.005).", "other/mixed: Dementia Risk in Type 2 Diabetes Patients: Acarbose Use and Its Joint Effects with Metformin and Pioglitazone — The hazard ratio for ever users versus never users was 0.841 (95% confidence interval, 0.704-1.005)", "other/mixed: Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males. — Acarbose increased male median lifespan by 22% (P < 0.0001)"], "limitations": ["This is an agent-assisted alpha memo, not a PRISMA-complete systematic review or clinical guideline.", "It is not PROSPERO-registered and should not be read as medical advice.", "Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."], "publication_id": "882d6167-8336-4714-87b4-501263f7898e", "screening": {"excluded": 0, "exclusion_reasons": ["No PRISMA full-text exclusion-stage filter was applied."], "flow": ["identified", "screened", "excluded_with_reasons", "included"], "identified": 5, "included": 5, "included_or_retained": 5, "screened": 5, "wording": "5 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit."}}
metadata
{
"researka_object_type": "publication_sidecar",
"researka_publication_id": "882d6167-8336-4714-87b4-501263f7898e",
"researka_submission_id": "eeb5d769-1a6c-4c98-961e-f0e8a368ae73",
"sidecar_name": "contradiction_map.json",
"sidecar_url": "https://api.researka.org/publications/882d6167-8336-4714-87b4-501263f7898e/sidecars/contradiction_map.json"
}